NCT04117347

Brief Summary

The purpose of this study is to determine the effect of different amounts of time of morning light on brain emotional processing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 7, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

January 24, 2020

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 8, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 8, 2023

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

March 26, 2024

Completed
Last Updated

December 27, 2024

Status Verified

December 1, 2024

Enrollment Period

3.1 years

First QC Date

October 3, 2019

Results QC Date

March 1, 2024

Last Update Submit

December 10, 2024

Conditions

Keywords

Circadian timingMoodLight

Outcome Measures

Primary Outcomes (1)

  • Change in Amygdala Reactivity as Measured by Blood-oxygen-level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal

    Participants completed the Emotional Faces Assessment Task (EFAT) during the fMRI scan. The average blood-oxygen-level-dependent (BOLD) signal change between the display of negative faces versus display of shapes was derived for the left and right amygdala separately. Higher levels indicate greater amygdala reactivity to negative faces versus display of shapes.

    Baseline and treatment week 2 and treatment week 4

Study Arms (3)

Light therapy A via the Re-Timer®

EXPERIMENTAL

-15 minutes/day

Device: Light therapy A via the Re-Timer®

Light therapy B via the Re-Timer®

EXPERIMENTAL

-30 minutes/day

Device: Light therapy B via the Re-Timer®

Light therapy C via the Re-Timer®

EXPERIMENTAL

-60 minutes/day

Device: Light therapy C via the Re-Timer®

Interventions

Subjects will conduct light treatment in the mornings at home.

Also known as: Re-Timer®
Light therapy A via the Re-Timer®

Subjects will conduct light treatment in the mornings at home.

Also known as: Re-Timer®
Light therapy B via the Re-Timer®

Subjects will conduct light treatment in the mornings at home.

Also known as: Re-Timer®
Light therapy C via the Re-Timer®

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Meets criteria for traumatic stress
  • Normal or corrected to normal vision
  • Right-handed
  • Fluency in English
  • Physically able to travel for study visit attendance

You may not qualify if:

  • Significant chronic uncontrolled disease (e.g. uncontrolled diabetes, advanced liver disease, cancer, etc.)
  • Severe hearing problem
  • Intellectual disability or serious cognitive impairment
  • Inability to tolerate enclosed spaces (e.g. the MRI machine)
  • Ferrous-containing metals within the body
  • Pregnant, trying to get pregnant, or breastfeeding
  • Epilepsy
  • Other research participation
  • Frequent number of special events during study period (weddings, concerts, exams, etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Related Publications (1)

  • Burgess HJ, Rizvydeen M, Huizenga B, Prasad M, Bahl S, Duval ER, Kim HM, Phan KL, Liberzon I, Abelson J, Klumpp H, Horwitz A, Mooney A, Raglan GB, Zalta AK. A 4-week morning light treatment reduces amygdala reactivity and clinical symptoms in adults with traumatic stress. Psychiatry Res. 2024 Dec;342:116209. doi: 10.1016/j.psychres.2024.116209. Epub 2024 Sep 21.

Related Links

Results Point of Contact

Title
Dr. Helen Burgess
Organization
University of Michigan

Study Officials

  • Helen Burgess

    University of Michigan

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The outcomes assessor will be blinded to study arm. The PI, study coordinator and research assistants will remain unblinded to perform safety assessments and provide feedback on intervention adherence. Blinded staff will wear buttons as an upfront visual cue to remind participants not to talk about their treatment.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Psychiatry

Study Record Dates

First Submitted

October 3, 2019

First Posted

October 7, 2019

Study Start

January 24, 2020

Primary Completion

March 8, 2023

Study Completion

March 8, 2023

Last Updated

December 27, 2024

Results First Posted

March 26, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

The researchers are open to sharing data by any appropriate mechanism indicated by NIH program staff. That includes that identified research information will be entered into the National Institute of Mental Health's Database for Clinical Trials related to Mental Illness (NDCT)

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
After scientific papers are accepted for publication and the data will be available for 7 years after study completion.
Access Criteria
Researchers requesting data will first have to sign a data sharing agreement, agreeing to the conditions of use governing access to the public release data, including restrictions against attempting to identify study participants, electronically securing the data while in use, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, no use of the data for commercial purposes and proper acknowledgement of the data resource.

Locations